Intelligent Bio Solutions Adds Major European Transport and Infrastructure Solutions Provider to Growing Number of Accounts Adopting Fingerprint Drug Screening Technology
12 Giugno 2024 - 2:30PM
Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the
"Company"), a medical technology company delivering intelligent,
rapid, non-invasive testing solutions, today announced the addition
of a major European transport and infrastructure solutions provider
to its growing number of accounts. The company is using INBS'
Intelligent Fingerprinting Drug Screening System to monitor fitness
for duty of employees within its United Kingdom operations.
The decision to integrate INBS’ innovative
technology into the company’s operations demonstrates its
commitment to employee safety and operational efficiency.
Previously, it used sporadic, for-cause urine testing involving a
third-party provider with a minimum two-hour call-out time. The
company wanted to implement random testing on-site that was quicker
and more efficient. INBS' solution facilitates in-house drug
testing, ensuring greater efficiency, a safer workplace and
compliance with industry standards and the company’s code of
conduct.
The addition of the European transport and
infrastructure solutions provider to INBS’ growing number of
accounts shows an increasing interest in its innovative technology
within the transport and infrastructure sectors. INBS’ existing
customer, VANTEC Europe Limited (“VANTEC”), is a global provider of
transportation and logistics solutions with 12 operations
throughout the UK. VANTEC has used INBS’ system since 2021, with
Diane Elgar, Head of Human Resources and Training at VANTEC Europe
Limited, previously sharing her positive experience with the
system.
"We are gaining traction within a significant
number of industries and have further solidified our position by
adding this leading transport and infrastructure solutions company
to our increasing number of accounts. This addition follows a
long-term relationship with an existing account in the same sector
that has been purchasing our products for three years. This is a
clear indication that we're not just acquiring new accounts but
also establishing enduring supply relationships," commented Harry
Simeonidis, President and CEO at INBS.
INBS’ first-of-its-kind solution uses
fingerprint sweat to provide a quick, hygienic, and easy-to-use
method for drug testing, delivering results in just minutes. This
unique approach tests for common drugs of abuse, including cocaine,
cannabis, methamphetamine, and opiates.
About Intelligent Bio Solutions
Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is
a medical technology company delivering innovative, rapid,
non-invasive testing solutions. The Company believes that its
Intelligent Fingerprinting Drug Screening System will revolutionize
portable testing through fingerprint sweat analysis, which has the
potential for broader applications in additional fields. Designed
as a hygienic and cost-effective system, the test screens for
recent use of drugs commonly found in the workplace, including
opiates, cocaine, methamphetamine, and cannabis. With sample
collection in seconds and results in under ten minutes, this
technology would be a valuable tool for employers in
safety-critical industries. Additionally, the Company's biosensor
platform has the potential to test for various indications, ranging
from immunological conditions to communicable diseases. The
Company's current customer segments include construction,
manufacturing and engineering, transport and logistics firms, drug
treatment organizations, and coroners.
For more information,
visit: http://www.ibs.inc/
Forward-Looking
Statements:
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. Forward-looking statements
in this press release include, without limitation, Intelligent Bio
Solutions Inc.'s ability to successfully develop and commercialize
its drug and diagnostic tests, realize commercial benefit from its
partnerships and collaborations, and secure regulatory approvals,
among others. Although Intelligent Bio Solutions Inc. believes that
the expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Intelligent Bio Solutions Inc. has
attempted to identify forward-looking statements by terminology,
including "believes," "estimates," "anticipates," "expects,"
"plans," "projects," "intends," "potential," "may," "could,"
"might," "will," "should," "approximately" or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are only predictions
and involve known and unknown risks, uncertainties, and other
factors, included in Intelligent Bio Solutions' public filings
filed with the Securities and Exchange Commission. Any
forward-looking statements contained in this release speak only as
of its date. Intelligent Bio Solutions undertakes no obligation to
update any forward-looking statements contained in this release to
reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
Company Contact: Intelligent Bio Solutions
Inc. info@ibs.inc LinkedIn | Twitter
Investor & Media Contact:Valter Pinto,
Managing DirectorKCSA Strategic CommunicationsPH: (212)
896-1254INBS@kcsa.com
Grafico Azioni Intelligent Bio Solutions (NASDAQ:INBS)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Intelligent Bio Solutions (NASDAQ:INBS)
Storico
Da Giu 2023 a Giu 2024